Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.

Medical Crossfire®: Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce long-term complications of bleeding, and arrest bleeding if it occurs. Health care providers should understand the underlying etiology and pathophysiology of hemophilia A. In addition, providers should be familiar with how patients perceive their disease and how health-related and economic burdens of hemophilia A impact patients and their families.

Acknowledgement of Commercial Support:

This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward hematologists, primary care clinicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the management of hemophilia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
  • Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
  • Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
  • Develop personalized prophylactic treatment plans for patients with hemophilia A

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 


Pasi A. Jänne, MD, PhD
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Medical Director, Pediatric Hemophilia and Coagulation Disorders Program
Medical Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Disclosures: Grant/Research Support: Siemens, YewSavin; Consultant: ApcinteX, ASC Therapeutics, Bayer Healthcare, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GeneVentiv Therapeutics, HEMA Biologics, Freeline Therapeutics, Novo Nordisk, Pfizer, F. Hoffmann-La Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda Pharmaceutical Company, Spark Therapeutics, uniQure.


Mary Beth Beasley, MD
Kenneth A. Bauer, MD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Kenneth A. Bauer, MD has no relevant financial relationships with ineligible companies

Gregory Riely, MD
Michelle L. Witkop, DNP, FNP-BC
Head of Research
Vice President, Research Strategy                    
National Hemophilia Foundation       
New York, NY

Disclosures: Consultant: F. Hoffmann-La Roche.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By